Key facts: Certara Bookings Up 4%; Losses Widen; Phoenix Cloud 10%
Certara (CERT) reported Q3 bookings up 4% to $92.5M, with software bookings rising 15%. Losses widened due to higher operating costs, but adjusted EBITDA was $83.1M. Phoenix cloud conversions are ahead of schedule, though may impact near-term revenue.
How this was made

The 30-second read
Why it matters
The mixed results could lead to short‑term price weakness but may set up longer‑term upside if cloud adoption accelerates.
Market read
First report of Q3 bookings and loss widening for Certara, offering fresh data for traders.
What to watch
Cloud migration could improve margins long‑term; current loss widening may be temporary.
Background
Certara is a provider of software and services for the life‑sciences industry.
Ticker impact
Certara reported Q3 bookings up 4% to $92.5M but wider losses, marking the first disclosure of these figures.
downward pressure as investors digest higher losses despite booking increase
Bookings growth is modest and cloud transition may delay revenue, while loss widening signals cost pressure.
Market effects
Signals potential slowdown in biotech software services revenue growth.
Limited to US biotech/software niche.
Low, as Certara is a small‑cap with niche exposure.
Counterpoint
Investors may view the booking increase as a positive tailwind despite losses.
Key entities
- CompanyCertara, Inc.
Life‑sciences software and services provider.




